Drugs / AVX-COVID/12
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05710783 | Nov → Dec 2022 | COVID-19 | Laboratorio Avi-Mex, S.A. de C.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX/COVID-12 | “This is a phase II/III parallel, double-blind, active-controlled, non-inferiority study to evaluate immunogenicity and safety of a booster immunization scheme of a single...” NCT05710783 ↗ |
| Modality | Vaccine | “recombinant vaccine against SARS-CoV-2” NCT05710783 ↗ |
| Route | Intramuscular | “single intramuscular dose” NCT05710783 ↗ |